Disease Control and Prevention Vaccine Market Size Expected To Reach a 12.1% CAGR By New Methods, Advanced Technologies, Top Company Profiles, Industry Share and Trends Analysis To 2025

SEATTLE, March 24, 2021, (PHARMIWEB) — Global Disease Control and Prevention Vaccine Market – Insights

Vaccine is a biological preparation that offer active acquired immunity to inhibit or control a particular disease or a group of disease. Vaccination against various bacterial and viral diseases is an integral part of infectious disease control worldwide and is done in adults and infants. According to European Centre for Disease Prevention and Control (ECDC), pertussis and invasive pneumococcal disease account for over 50% of vaccine preventable disease and over 60% of deaths. The completion of immunization schedule from infant to adulthood decreases the burden of vaccine preventable disease significantly. According to the World Health Organization (WHO)’s, 2018 factsheet, immunization averts around 2 to 3 million deaths annually around the globe. Furthermore, according to the same source, around 1.5 million deaths can be prevented by improving vaccine coverage across the globe.

Note: *The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1500

The global disease control and prevention vaccine market was estimated to be valued at US$ 41.12 billion in 2017 and is expected to exhibit a CAGR of 12.1 % during the forecast period (2017–2025).

Global Disease Control and Prevention Vaccine Market, By Product Type

Source: Coherent Market Insights Analysis (2018)

Growing Prevalence of Infectious Diseases is Expected to Propel Growth of the Global Disease Control and Prevention Vaccine Market

High prevalence and growing occurrence of infectious disease are expected to drive growth of the global disease control and prevention vaccine market. According to the study published in journal Lancet Infectious Disease, between January 2004 and December 2013, around 54,984,661 cases of 45 infectious diseases were reported with average yearly incidence 417·98 per 100,000 in China. Furthermore, according to the same source, Hepatitis B and tuberculosis (TB) has high incidence rate of 81.57 and 80.33 per 100,000, respectively. Moreover, according to the World Health Organization (WHO), in 2016, around 212 million malaria cases were reported with the highest incidence in African regions.

The vaccines manufactured with innovative technologies such as recombinant technology or cell-based vaccine production is reducing the gap between demand and supply, which is expected to the global disease control and prevention vaccine market growth in the near future. For instance, in 2013, Protein Science Corporation received the U.S. Food and Drug Administration (FDA) approval for Flubok Trivalent Vaccine, produced by recombinant technology in the U.S. Moreover, in 2016, Seqirus received the U.S. FDA approval for Flucelvax Quadrivalent, cell-culture derived influenza vaccine.

Exclusive offer!!! Purchase the report at a discounted rate!!!

Apply Promo Code “CMIFIRST1000” and Get Up to 30% Discount

Quick Buy – Disease Control and Prevention Vaccine Market Research Report: https://bit.ly/3ci4VJe

Increasing Governmental Initiatives for Immunization Programs to Propel Growth of the Global Disease Control and Prevention Vaccine Market

Governmental and non-governmental organization are collaborating to provide better immunization to population for complete disease eradication. For instance, the Global Polio Eradication Initiative was a public-private partnership between five governmental agencies – the World Health Organization (WHO), Rotary International, the U.S. Centers for Disease Control and Prevention (CDC), the United Nations Children’s Fund (UNICEF) and the Bill & Melinda Gates Foundation, which was aimed at polio eradication worldwide. The program was funded US$ 15 billion in the period 1988 – 2017, provided by public and private donors and 2013 – 2019 requirement was projected to US$ 7 billion. Furthermore, organization such as CDC, the U.S. FDA, and the National Institutes of Health (NIH) have collaborated with the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) to support development of advanced influenza vaccines. Hence, such governmental initiatives are expected to drive growth of the global disease control and prevention vaccine market during the forecast period (2017-2025). However, high cost of vaccine development is expected to hinder growth of the global disease control and prevention vaccine market.

To understand Research Methodology, please click https://www.coherentmarketinsights.com/market-insight/disease-control-and-prevention-vaccine-market-1500

According to Access to Medicine Foundation index, in 2017, four companies the vaccine market, collectively referred as ‘big four’: GSK, Merck & Co., Inc., Pfizer, and Sanofi. The big four account for 80% of the global vaccine revenue. Players vary significantly by portfolio and pipeline size. Other major players operating in the global disease control and prevention vaccine market include AstraZeneca PLC, Sinovac Biotech Ltd., Astellas Pharma Inc., Serum Institute of India Pvt. Ltd., and Daiichi Sankyo.

Table of Content

Global Disease Control and Prevention Vaccine Market Research Report
Section 1: Global Disease Control and Prevention Vaccine Industry Overview
Section 2: Global Economic Impact on Disease Control and Prevention Vaccine Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Disease Control and Prevention Vaccine Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Disease Control and Prevention Vaccine Market Forecast

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837